Craig Cameron, MD
Clinical Cardiac Electrophysiology · Tulsa, OKNPI 1356472583
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,938 of the $52,051 with a category attached, or 80.6%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 64.6% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $17,052, 2.5 times the $6,828 reported in 2019.
Across 280 payments — averaging $185.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$34K
- Boston Scientific$11K
- Medtronic$2K
- Abbott$1K
- Biosense Webster, Inc.$1K
- Philips North America LLC$939
- plus $1K from 11 others
Across 21 payments — averaging $1765.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medical Device Business Services, Inc.$25K
- ZOLL Respicardia, Inc.$12K
What the payments were for
- Consulting fees$9002%
- Speaking & faculty fees$41,93881%
- Travel & lodging$2,0514%
- Food & beverage$7,10414%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 41 | $33,646 |
| Boston Scientific | 79 | $11,423 |
| Medtronic(2 entities) | 24 | $2,147 |
| Abbott | 35 | $1,416 |
| Biosense Webster, Inc. | 61 | $1,059 |
| Philips North America LLC | 4 | $939 |
| ZOLL Respicardia, Inc. | 3 | $566 |
| Abiomed | 5 | $319 |
| E.r. Squibb & Sons, L.L.C. | 7 | $166 |
| Johnson & Johnson | 9 | $163 |
| Pfizer | 6 | $88 |
| Atricure, Inc. | 1 | $34 |
| Amgen | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Teleflex LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$32,456
- GENERAL EP$9,688
- EVERA MRI XT DR SURESCAN$1,215
- TightRail$900
- AVEIR$650
- remede System$566
- Carto 3$389
- Micra$257
- WATCHMAN Access System$240
- Watchman$220
- RHYTHMIA$146
- OCTARAY MAPPING CATHETER$145
- Quadra Assura CRT Defibrillator$140
- Impella$117
- EnSite Precision Cardiac Mapping System$112
- WATCHMAN FLX$110
How this compares
$52,051 in reported general payments places this provider in the 75th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.
See all clinical cardiac electrophysiology providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 702 | $647,254 |
| XareltoRivaroxaban | 166 | $179,852 |
| EntrestoSacubitril/Valsartan | 11 | $10,077 |
| MultaqDronedarone Hcl | 11 | $8,384 |
| Metoprolol Succinate | 346 | $6,815 |
| Dofetilide | 19 | $4,577 |
| Flecainide Acetate | 106 | $2,768 |
| Amiodarone Hcl | 119 | $2,299 |
| Metoprolol Tartrate | 120 | $1,125 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 37 | $728 |
| Carvedilol | 62 | $672 |
| ClopidogrelClopidogrel Bisulfate | 41 | $612 |
| Mupirocin | 64 | $450 |
| Warfarin Sodium | 35 | $370 |
| Losartan Potassium | 14 | $263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $647,254702 claims |
| Johnson & JohnsonXarelto | $163 | $179,852166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.
Other clinical cardiac electrophysiology in Tulsa
- David SandlerTulsa$86K
- Vikram KatariTulsa$34K
- Venkatesh RaviTulsa$31K
- James ComanTulsa$24K
- Joseph GardTulsa$23K
- Ele WuTulsa$22K
- Andrew HinojosTulsa$17K
- David OkadaTulsa$16K
- Warren JackmanOklahoma City$2.3M
- Sunny PoOklahoma City$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.